A5027487279- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- RNA Interference and Gene Delivery
- SARS-CoV-2 and COVID-19 Research
- CRISPR and Genetic Engineering
- CAR-T cell therapy research
- Protein purification and stability
McGill University
2019-2023
The field of lentiviral vector (LV) production continues to face challenges in large-scale manufacturing, specifically regarding producing enough vectors meet the demand for treating patients as well high and consistent quality efficient dosing. Two areas interest are use stable producer cell lines, which facilitates scalability LV processes making process more reproducible robust clinical applications, search a retention device scalable industrial-size bioreactors. This manuscript...
The administration of viral vectored vaccines remains one the most effective ways to respond ongoing novel coronavirus disease 2019 (COVID-19) pandemic. However, pre-existing immunity vector hinders its potency, resulting in a limited choice vectors. Moreover, basic batch mode manufacturing does not allow cost-effectively meet global demand for billions doses per year. To date, exposure humans VSV infection has been limited. Therefore, recombinant vesicular stomatitis virus (rVSV), which...
Lentiviral vectors (LVs) are a popular gene delivery tool in cell and therapy they primary for ex vivo transduction of T cells expression chimeric antigen receptor (CAR) CAR-T therapies. Extensive process product characterization required manufacturing virus-based to better control batch-to-batch variability. However, it has been an ongoing challenge make quantitative assessments LV because current analytical tools often low throughput lack robustness standardization is still required. This...
There have been considerable efforts on improving the lentiviral vector (LV) system and their production. However, there remains persisting challenge of producing a sufficient quantity LVs at manufacturing scale to support treatments beyond early clinical trials. Furthermore, innately labile nature poses an equally important obstacle in LV As lose function over time they are sensitive environmental factors each unit operation bioprocess workflow, integrated continuous is attractive strategy...